Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Warfarin
Drug ID BADD_D02373
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
Marketing Status Discontinued; Prescription
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D08682
MeSH ID D014859
PubChem ID 54678486
TTD Drug ID D0E3OF
NDC Product Code 50090-2582; 71610-462; 76282-329; 50090-2613; 51407-341; 51407-342; 43353-028; 70934-821; 51407-347; 43353-023; 65162-763; 70934-820; 76282-328; 65162-769; 71610-448; 50090-3263; 71335-1786; 70518-2816; 65162-762; 76282-333; 71335-1824; 70934-911; 43353-053; 50090-2654; 76282-335; 65162-764; 43353-029; 65162-766; 70518-2382; 50090-2936; 51407-348; 65162-767; 43353-054; 65162-761; 50090-2646; 43353-030; 51407-343; 51407-346; 70518-2381; 43353-021; 50090-2586; 70518-2717; 76282-334; 50090-5058; 76282-331; 71610-490; 71610-491; 76282-332; 43353-033; 71610-519; 65162-765; 50090-2645; 70934-587; 76282-327; 70518-2383; 65162-768; 51407-349; 70518-2395; 71335-1595; 50090-2617; 51407-344; 51407-345; 71610-458; 70518-2380; 70518-2394; 76282-330
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H16O4
CAS Registry Number 81-81-2
SMILES CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Coagulation time shortenedCytochrome P450 2C19P33261Not Available1109248; 806430; 1580446; 5006877; 806430; 5458032; 1109248; 15871634; 15487810; 15324521; 9200780; 624779; 12841813; 6690067; 3719899; 6499359
HaemorrhageCytochrome P450 2C9P11712T1924410073515; 11926893; 10961881
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Extravasation08.01.03.008--Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.0010.000841%Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial bones fracture15.08.04.001; 12.04.05.0020.000120%Not Available
Facial paralysis17.04.03.0080.000481%Not Available
Factor VIII deficiency03.15.01.002; 01.01.01.0050.000120%Not Available
Faeces discoloured07.01.03.0020.004805%Not Available
Faeces hard07.01.03.0030.000120%Not Available
Failure to thrive19.07.05.001; 18.04.01.003; 14.03.02.008--Not Available
Fat embolism24.01.01.012; 12.01.08.0030.000360%Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.002--
Feeling abnormal08.01.09.014--Not Available
Feeling cold08.01.09.0080.000541%Not Available
Feeling hot08.01.09.009--Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Fistula15.03.02.0010.000180%Not Available
Flank pain15.03.04.003; 08.01.08.007; 20.02.03.0060.000481%
Flatulence07.01.04.002--
Fluid overload14.05.06.001; 02.05.04.004--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Food interaction08.06.03.0020.000721%Not Available
Foot fracture15.08.03.012; 12.04.01.012--Not Available
Fracture15.08.02.001; 12.04.02.001--
Frequent bowel movements07.02.04.002--Not Available
Fungal infection11.03.05.001--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 37 Pages